Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of theIDH1-R132HMutation in Diffuse Glioma Biopsy Specimens

Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation

(2011) Mika Kato Kaneko et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas

(2011) Craig Horbinski et al.   BRAIN PATHOLOGY

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing

(2010) Jörg Felsberg et al.   ACTA NEUROPATHOLOGICA

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

(2010) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology

(2010) David Capper et al.   ACTA NEUROPATHOLOGICA

Molecular diagnostics of gliomas: state of the art

(2010) Markus J. Riemenschneider et al.   ACTA NEUROPATHOLOGICA

Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes

(2010) David Capper et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations

(2010) Andreas Von Deimling et al.   BRAIN PATHOLOGY

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

(2010) Houtan Noushmehr et al.   CANCER CELL

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

(2010) M. J. van den Bent et al.   CLINICAL CANCER RESEARCH

Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies

(2010) Craig Horbinski et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Pyrosequencing-Based Assay for the Rapid Detection of IDH1 Mutations in Clinical Samples

(2010) Prashanth Setty et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma

(2010) Brock C. Christensen et al.   JNCI-Journal of the National Cancer Institute

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

(2010) C. Houillier et al.   NEUROLOGY

Monoclonal antibody specific for IDH1 R132H mutation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma

(2009) Andrey Korshunov et al.   ACTA NEUROPATHOLOGICA

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas

(2009) Christian Hartmann et al.   ACTA NEUROPATHOLOGICA

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

(2009) Yukinari Kato et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PCR- and Restriction Endonuclease-Based Detection ofIDH1Mutations

(2009) Jochen Meyer et al.   BRAIN PATHOLOGY

Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors

(2009) David Capper et al.   BRAIN PATHOLOGY

IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

(2009) S. Nobusawa et al.   CLINICAL CANCER RESEARCH

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas

(2009) Marc Sanson et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic Use ofIDH1/2Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues

(2009) Craig Horbinski et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

(2009) Koichi Ichimura et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of the IDH1 codon 132 mutation in brain tumors

(2008) Jörg Balss et al.   ACTA NEUROPATHOLOGICA

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE